RxDoctor Payments Data

Hunter Huston, MD

Nephrology · Nashville, TNNPI 1861751703

Payments from drug & device makers

What this record shows

The money is spread across several categories — consulting fees (59.7%), speaking fees and food and beverage — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 90.3% of it on its own, with 12 other manufacturers making up the rest. Reporting peaked in 2022 at $5,551 and has fallen 97.5% since, to $136 in 2025.

$8,611in general payments, 2019–2025

Across 59 payments — averaging $145.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$8K
  • Otsuka America Pharmaceutical, Inc.$309
  • Outset Medical Inc$158
  • Nxstage Medical, Inc.$118
  • Amgen$82
  • Pfizer$32
  • plus $131 from 7 others

What the payments were for

  • Consulting fees$5,13960%
  • Speaking & faculty fees$2,20026%
  • Food & beverage$1,12313%
  • Education$1492%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$8,611 in reported general payments places this provider in the 80th percentile of 229 nephrology providers in Tennessee.

See all nephrology providers in Tennessee

Medicare billing

Part B allowed, 2024
$83,218
Medicare patients
364
Services billed
967

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol19$24,695
JardianceEmpagliflozin12$9,601
Nifedipine ErNifedipine36$975
Calcium Acetate13$712
Losartan Potassium53$430
Calcitriol30$421
Tamsulosin Hcl23$295
Allopurinol28$249
Chlorthalidone18$222
Furosemide37$221
Potassium Chloride12$214
Amlodipine Besylate20$167
Carvedilol12$166
Spironolactone16$78
Lisinopril11$52

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga$7,779$24,69519 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 229 nephrology providers in Tennessee.

Other nephrology in Nashville

See the full list for Tennessee

Where these figures come from

Is this you, or does something look wrong? →